Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience

Abstract Background Low‐molecular‐weight heparin has been the preferred treatment of cancer‐associated thrombosis (CAT); however, emerging data support the use of direct oral anticoagulants (DOACs). Objectives The Memorial Sloan Kettering Cancer Center Clinical Pathway has served as the institutiona...

Full description

Bibliographic Details
Main Authors: Gerald A. Soff, Jodi Mones, Cy Wilkins, Sean Devlin, Eva Haegler‐Laube, Jonathan Wills, Debra M. Sarasohn, Krishna Juluru, Michael Singer, Yimei Miao, Jeanette Batista, Simon Mantha
Format: Article
Language:English
Published: Wiley 2019-07-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
aged
hemorrhage
neoplasms
rivaroxaban
venous thromboembolism
Online Access:https://doi.org/10.1002/rth2.12215

Internet

https://doi.org/10.1002/rth2.12215

Similar Items